Science

Apr 7, 2025, 09:36

Myeloma Paper of the Day, April 7th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Venetoclax combos in relapsed/refractory myeloma – ORR of 57% (64% in t (11;14), 26% in non-t (11;14) with hi BCL2), PFS 9.4 mos (11.8 for t (11;14) vs. 2.9 months for non); presence of del (17p) or +1q reduced PFS to 7.7 mos.”

“Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes”

Authors: Abiola Bolarinwa, Madhu Nagaraj, Saurabh Zanwar, Nadine Abdallah, Leif Bergsagel, Linda Baughn, Vincent Rajkumar, Rafael Fonseca, Sikander Ailawadhi, Shaji Kumar et al.

More posts featuring Robert Orlowski.

Abiola Bolarinwa cancer Leif Bergsagel Linda Baughn Madhu Nagaraj multiple myeloma Myeloma Paper of the Day Nadine Abdallah OncoDaily Oncology Rafael Fonseca relapsed/refractory multiple myeloma Robert Orlowski RRMM Saurabh Zanwar Shaji Kumar Sikander Ailawadhi Vincent Rajkumar

Can Joe Lonsdale Become the Elon Musk of FDA Reform?

In Memory of Robert Kardashian: His Courageous Battle with Esophageal Cancer

The Essential Medicines for Children with Cancer: From Access to Action by OncoDaily

Martin Makary Becomes the 27th FDA Commissioner

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution